Creative Planning’s Agile Therapeutics AGRX Stock Holding History

Creative Planning’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5	Closed	-$2K	–	2589
2022 Q1	$2K	Hold	5	–	–	﹤0.01%	2311
2021 Q4	$5K	Hold	5	–	–	﹤0.01%	2069
2021 Q3	$10K	Hold	5	–	–	﹤0.01%	2076
2021 Q2	$13K	Hold	5	–	–	﹤0.01%	2008
2021 Q1	$21K	Sell	5 -9	-64%	-$48.6K	﹤0.01%	2433
2020 Q4	$78K	Hold	14	–	–	﹤0.01%	2054
2020 Q3	$82K	Hold	14	–	–	﹤0.01%	1854
2020 Q2	$75K	Hold	14	–	–	﹤0.01%	1711
2020 Q1	$50K	Buy	14 +9	+180%	+$51.7K	﹤0.01%	1632
2019 Q4	$25K	Hold	5	–	–	﹤0.01%	1864
2019 Q3	$12K	Hold	5	–	–	﹤0.01%	1895
2019 Q2	$15K	Hold	5	–	–	﹤0.01%	1910
2019 Q1	$15K	Hold	5	–	–	﹤0.01%	1858
2018 Q4	$6K	Hold	5	–	–	﹤0.01%	1864
2018 Q3	$4K	Buy	+5	New	+$3.66K	﹤0.01%	2023
2015 Q1	–	Hold	0	–	–	–	4460
2014 Q4	–	Hold	0	–	–	–	4395

Other funds holding AGRX

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Creative Planning's AGRX Position: Q2 2022 in Review

Creative Planning sold out of Agile Therapeutics (AGRX) in Q2 2022, closing a stake of 5 shares — an estimated $2K sold.

Creative Planning first reported a position in AGRX in Q3 2018 and held it in 15 quarters. The position peaked at $82K in Q3 2020. 19 funds tracked by Wall St. Rank hold AGRX as of Q2 2022.

Creative Planning reported no remaining Agile Therapeutics position as of Q2 2022 after selling out during the quarter.
Creative Planning sold 5 Agile Therapeutics shares in Q2 2022, an estimated $2K.
Creative Planning first reported a position in Agile Therapeutics in Q3 2018 and held it in 15 quarters.
Creative Planning's Agile Therapeutics position peaked at $82K in Q3 2020.
19 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2022.

Based on Creative Planning's 13F filing for Q2 2022, filed 15 Aug 2022.